Market Overview

UPDATE: Catalyst Biosciences Says Interim Data From Phase 2/3 Study Of Marzeptacog Alfa SUpports Goal Of Significantly Reducing Annualized Bleed Rates With Daily Subcutaneous Injections Of Marzeptacog Alfa

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: News FDA Press Releases

 

Related Articles (CBIO)

Cleveland-Cliffs, L Brands, Lowe's, Snap: 'Fast Money' Final Trades For July 18

A Peek Into The Markets: US Stock Futures Flat; Morgan Stanley Earnings In Focus